Muntau, A., Burlina, A., Eyskens, F., Freisinger, P., Leuzzi, V., Sivri, H. S., . . . Rutsch, F. (2021). Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: Results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial. Orphanet journal of rare diseases, 16, . https://doi.org/10.1186/s13023-021-01968-1
Chicago-Zitierstil (17. Ausg.)Muntau, Ania, et al. "Long-term Efficacy and Safety of Sapropterin in Patients Who Initiated Sapropterin at < 4 years of Age with Phenylketonuria: Results of the 3-year Extension of the SPARK Open-label, Multicentre, Randomised Phase IIIb Trial." Orphanet Journal of Rare Diseases 16 (2021). https://doi.org/10.1186/s13023-021-01968-1.
MLA-Zitierstil (9. Ausg.)Muntau, Ania, et al. "Long-term Efficacy and Safety of Sapropterin in Patients Who Initiated Sapropterin at < 4 years of Age with Phenylketonuria: Results of the 3-year Extension of the SPARK Open-label, Multicentre, Randomised Phase IIIb Trial." Orphanet Journal of Rare Diseases, vol. 16, 2021, https://doi.org/10.1186/s13023-021-01968-1.